Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir Intensification in Virologically Suppressed HIV
NCT06819176Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenacapavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Changes in the intact HIV proviral reservoir size at 96 weeks. Started Jan 2026; status: recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06819176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819176.